While three United States Food and Drug Administration‐approved CDK4/6 inhibitors are mainly used for ER+ breast cancer in combination with endocrine therapy, a recent study has demonstrated single‐agent activity of a newer CDK4/6 inhibitor, abemaciclib, in the treatment of ER+ metastatic breast cancer.51 This evidence concerns the gene ESR1 and breast cancer.